Wiener Medizinische Wochenschrift

, Volume 160, Issue 1–2, pp 30–38 | Cite as

Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus

  • Serdar Farhan
  • Thomas Höchtl
  • Alexandra Kautzky-Willer
  • Johann Wojta
  • Kurt Huber
Themenschwerpunkt

Summary

Diabetes mellitus (DM) is a life-threatening disease. Patients with DM have a 2- to 4-fold higher risk of developing cardiovascular disease compared to their non-diabetic counterparts. Several drugs are available for the treatment of stable coronary artery disease (CAD) and acute coronary syndrome (ACS). Among oral antiplatelet agents (acetylsalicylic acid, ticlopidine, clopidogrel, and prasugrel), prasugrel has shown the highest efficacy in patients with DM and ACS. The use of glycoprotein IIb–IIIa receptor inhibitors in diabetic subjects with ACS undergoing percutaneous coronary intervention (PCI) reduces adverse clinical events in a greater extent than in non-diabetics. Several direct and indirect antithrombins are recommended for the treatment of ACS such as unfractionated heparin (UFH), enoxaparin, fondaparinux, and bivalirudin. Enoxaparin and bivalirudin have been shown to be superior to UFH among patients with ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) also in diabetic subgroup analyses.

Keywords

Coronary artery disease Acute coronary syndrome Diabetes mellitus 

Antithrombotische Therapie bei Patienten mit koronarer Herzkrankheit und Typ2 Diabetes mellitus

Zusammenfassung

Die koronare Herzerkrankung (KHK) ist die führende Mortalitätsursache bei Patienten mit Diabetes mellitus (DM). Die Langzeitprognose des Diabetikers ohne Myokardinfarkt-Anamnese ist vergleichbar mit der eines Patienten, der einen Myokardinfarkt (MI) bereits durchgemacht hat, aber keinen DM hat. Der Antiplättchen-Therapie bei Patienten mit einer KHK und DM kommt eine zentrale Rolle zu, wobei dem ADP-Rezeptorblocker Prasugrel eine größere Effizienz zugeschrieben wird im Vergleich zu Clopidogrel und Ticlopidin. Patienten mit DM und akuten Koronarsyndrom (ACS), die einer interventionellen Therapie unterzogen werden, profitieren mehr von eine additiven Therapie mit Glycoprotein IIb/IIIa-Inhibitoren als Patienten ohne DM. Weiters kommen verschiedene, direkte und indirekte Antithrombine in der Therapie des ST-Hebungs-Infarktes (STEMI) und nicht ST-Hebungs-Infarktes (NSTEMI) zur Anwendung. Unter diesen Medikamenten haben sich sowohl das niedermoleklare Heparin Enoxaparin als auch der direkte Thrombin-Inhibitor Bivalirudin als sicher und effizient bei Diabetikern im Vergleich zu unfraktionierten Heparin erwiesen.

Schlüsselwörter

Koronare Herzerkrankung Akutes Koronarsyndrom Diabetes mellitus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16: 434–444, 1993CrossRefPubMedGoogle Scholar
  2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339(4): 229–234, 1998CrossRefPubMedGoogle Scholar
  3. Cantrill JA, D'Emanuele A, Dornan TL, Garcia S. A survey of drug treatment and outcomes in diabetic patients with acute myocardial infarcts. J Clin Pharm Ther, 20(4): 207–213, 1995CrossRefPubMedGoogle Scholar
  4. MacDonald TM, Butler R, Newton RW, Morris AD. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration. Diabet Med, 15(4): 282–289, 1998CrossRefPubMedGoogle Scholar
  5. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The national heart, lung, and blood institute percutaneous transluminal coronary angioplasty registry. Circulation, 94(8): 1818–1825, 1996PubMedGoogle Scholar
  6. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation, 91(4): 979–989, 1995PubMedGoogle Scholar
  7. Reaven GM. Insulin resistance and human disease: a short history. J Basic Clin Physiol Pharmacol, 9(2–4): 387–406, 1998PubMedGoogle Scholar
  8. Pahor M, Psaty BM, Furberg CD. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol, 32(Suppl 2): S18–S23, 1998PubMedGoogle Scholar
  9. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care, 26(7): 2181–2188, 2003CrossRefPubMedGoogle Scholar
  10. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res, 5(2): 138–144, 2008CrossRefPubMedGoogle Scholar
  11. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med, 322(25): 1769–1774, 1990PubMedCrossRefGoogle Scholar
  12. Colwell JA. Aspirin therapy in diabetes. Diabetes Care, 20(11): 1767–1771, 1997PubMedGoogle Scholar
  13. Gawaz M, Ott I, Reininger AJ, Neumann FJ. Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb Haemost, 72(6): 912–918, 1994PubMedGoogle Scholar
  14. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care, 24(8): 1476–1485, 2001CrossRefPubMedGoogle Scholar
  15. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis, 8(1): 68–72, 1988PubMedGoogle Scholar
  16. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes, 47(2): 290–293, 1998CrossRefPubMedGoogle Scholar
  17. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med, 82(6): 733–738, 1975PubMedGoogle Scholar
  18. Shechter M, Merz CN, Paul-Labrador MJ, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol, 35(2): 300–307, 2000CrossRefPubMedGoogle Scholar
  19. Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes, 55(6): 1807–1812, 2006CrossRefPubMedGoogle Scholar
  20. Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GD, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes, 41(8): 909–913, 1992CrossRefPubMedGoogle Scholar
  21. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes, 43(1): 104–109, 1994CrossRefPubMedGoogle Scholar
  22. Davi G, Gennaro F, Spatola A, Catalano I, Averna M, Montalto G, et al. Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diabetes Complications, 6(1): 7–11, 1992CrossRefPubMedGoogle Scholar
  23. Nagai T. Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy. J Atheroscler Thromb, 1(1): 37–40, 1994PubMedGoogle Scholar
  24. Lopez Y, Paloma MJ, Rifon J, Cuesta B, Paramo JA. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res, 93(2): 71–78, 1999CrossRefPubMedGoogle Scholar
  25. Eliasson M, Asplund K, Evrin PE, Lindahl B, Lundblad D. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism, 43(12): 1579–1586, 1994CrossRefPubMedGoogle Scholar
  26. Farhan S, Winzer C, Tura A, Quehenberger P, Bieglmaier C, Wagner OF, et al. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes. Eur J Clin Invest, 36(5): 345–352, 2006CrossRefPubMedGoogle Scholar
  27. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry, 66(2): 255, 1999CrossRefPubMedGoogle Scholar
  28. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324(7329): 71–86, 2002Google Scholar
  29. Cubbon RM, Gale CP, Rajwani A, Abbas A, Morrell C, Das R, et al. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care, 31(2): 363–365, 2008CrossRefPubMedGoogle Scholar
  30. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care, 26(12): 3264–3272, 2003CrossRefPubMedGoogle Scholar
  31. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337: a1840, 2008CrossRefPubMedGoogle Scholar
  32. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 300(18): 2134–2141, 2008CrossRefPubMedGoogle Scholar
  33. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation, 82(1): 17–26, 1990PubMedGoogle Scholar
  34. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J, 29(23): 2909–2945, 2008CrossRefPubMedGoogle Scholar
  35. Kushner FG, Hand M, Smith SC Jr., King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 54(23): 2205–2241, 2009Google Scholar
  36. Szuk T, Gyongyosi M, Homorodi N, Kristof E, Kiraly C, Edes IF, et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J, 153(2): 289–295, 2007CrossRefPubMedGoogle Scholar
  37. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet, 348(9038): 1329–1339, 1996Google Scholar
  38. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 345(7): 494–502, 2001CrossRefPubMedGoogle Scholar
  39. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 288(19): 2411–2420, 2002CrossRefPubMedGoogle Scholar
  40. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation, 115(6): 708–716, 2007CrossRefPubMedGoogle Scholar
  41. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 357(20): 2001–2015, 2007CrossRefPubMedGoogle Scholar
  42. Wrishko RE, Ernest CS 2nd, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol, 49(8): 984–998, 2009CrossRefPubMedGoogle Scholar
  43. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J, 27(10): 1166–1173, 2006CrossRefPubMedGoogle Scholar
  44. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol, 51(21): 2028–2033, 2008CrossRefPubMedGoogle Scholar
  45. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J, 29(20): 2473–2479, 2008CrossRefPubMedGoogle Scholar
  46. Spinler SA, Rees C. Review of prasugrel for the secondary prevention of atherothrombosis. J Manag Care Pharm, 15(5): 383–395, 2009PubMedGoogle Scholar
  47. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation, 118(16): 1626–1636, 2008CrossRefPubMedGoogle Scholar
  48. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, 373(9665): 723–731, 2009CrossRefPubMedGoogle Scholar
  49. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361(11): 1045–1057Google Scholar
  50. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation, 104(23): 2767–2771, 2001CrossRefPubMedGoogle Scholar
  51. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation, 100(25): 2477–2484, 1999PubMedGoogle Scholar
  52. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of platelet IIb/IIIa inhibition in stenting investigators. N Engl J Med, 341(5): 319–327, 1999CrossRefPubMedGoogle Scholar
  53. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation, 110(24): 3627–3635, 2004CrossRefPubMedGoogle Scholar
  54. De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis, 207(1): 181–185, 2009CrossRefPubMedGoogle Scholar
  55. Fox KA, Antman EM, Cohen M, Bigonzi F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol, 90(5): 477–482, 2002CrossRefPubMedGoogle Scholar
  56. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation, 100(15): 1593–1601, 1999PubMedGoogle Scholar
  57. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med, 337(7): 447–452, 1997CrossRefPubMedGoogle Scholar
  58. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA, 292(1): 45–54, 2004CrossRefPubMedGoogle Scholar
  59. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA, 292(1): 89–96, 2004CrossRefPubMedGoogle Scholar
  60. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 28(13): 1598–1660, 2007CrossRefPubMedGoogle Scholar
  61. Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA, 294(20): 2594–2600, 2005CrossRefPubMedGoogle Scholar
  62. Baird SH, Menown IB, McBride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J, 23(8): 627–632, 2002CrossRefPubMedGoogle Scholar
  63. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of heparin and aspirin reperfusion therapy (HART II). Circulation, 104(6): 648–652, 2001CrossRefPubMedGoogle Scholar
  64. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 358(9282): 605–613, 2001Google Scholar
  65. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation, 108(2): 135–142, 2003CrossRefPubMedGoogle Scholar
  66. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation, 112(25): 3855–3867, 2005CrossRefPubMedGoogle Scholar
  67. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25). Am Heart J, 149(2): 217–226, 2005CrossRefPubMedGoogle Scholar
  68. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med, 354(14): 1477–1488, 2006CrossRefPubMedGoogle Scholar
  69. Morrow DA, Antman EM, Murphy SA, Qin J, Ruda M, Guneri S, et al. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J, 154(6): 1078–1084, 84 e1, 2007CrossRefPubMedGoogle Scholar
  70. Zeymer U, Gitt A, Zahn R, Junger C, Bauer T, Heer T, et al. Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. EuroIntervention, 4(4): 524–528, 2009PubMedGoogle Scholar
  71. Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, et al. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol, 45(12): 1932–1938, 2005CrossRefPubMedGoogle Scholar
  72. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 51(17): 1645–1652, 2008CrossRefPubMedGoogle Scholar
  73. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV Jr, Feit F, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 51(18): 1734–1741, 2008CrossRefPubMedGoogle Scholar
  74. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol, 52(10): 807–814, 2008CrossRefPubMedGoogle Scholar
  75. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet, 374(9696): 1149–1159, 2009CrossRefPubMedGoogle Scholar
  76. Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, et al. Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the fifth organization to assess strategies in acute ischemic syndromes investigators (OASIS-5) trial. Am Heart J, 157(5): 845–852, 2009CrossRefPubMedGoogle Scholar
  77. Peters R, SR M. Mortality benefit of fondaparinux versus enoxaparin in diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS): a subanalysis of OASIS-5. J Thromb Haemost, 5(Supplement 2): P-M-683, 2007Google Scholar
  78. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA, 295(13): 1519–1530, 2006CrossRefPubMedGoogle Scholar
  79. Oldgren J, Wallentin L, Afzal R, Bassand JP, Budaj A, Chrolavicius S, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J, 29(3): 315–323, 2008CrossRefPubMedGoogle Scholar
  80. Peters RJ, Joyner C, Bassand JP, Afzal R, Chrolavicius S, Mehta SR, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J, 29(3): 324–331, 2008CrossRefPubMedGoogle Scholar
  81. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet, 374(9683): 29–38, 2009CrossRefPubMedGoogle Scholar
  82. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation, 119(22): 2877–2885, 2009CrossRefPubMedGoogle Scholar
  83. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet, 374(9692): 787–795, 2009CrossRefPubMedGoogle Scholar
  84. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J, 158(3): 335–341 e3, 2009CrossRefPubMedGoogle Scholar
  85. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet, 373(9667): 919–928, 2009CrossRefPubMedGoogle Scholar
  86. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: study design and rationale. Am Heart J, 158(3): 327–334 e4, 2009Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Serdar Farhan
    • 1
  • Thomas Höchtl
    • 1
  • Alexandra Kautzky-Willer
    • 2
  • Johann Wojta
    • 3
  • Kurt Huber
    • 1
  1. 1.Third Department of Cardiology and Emergency MedicineWilhelminen HospitalViennaAustria
  2. 2.Third Department of Endocrinology and MetabolismUniversity of MedicineViennaAustria
  3. 3.Second Department of CardiologyUniversity of MedicineViennaAustria

Personalised recommendations